Endocyte, Inc. (ECYT)

Trade ECYT now with
10/18/2018 2:16:42 PM Wedbush Cuts Endocyte, Inc. (ECYT) To Neutral From Outperform With $24 Down From $25 Price Target
9/14/2018 4:11:08 PM Endocyte Announces Closing Of Public Offering Of Common Stock
9/11/2018 9:33:43 PM Endocyte Prices Underwritten Registered Public Offering Of 9.46 Mln Shares At $18.50/shr
9/10/2018 8:04:40 AM Endocyte Announces FDA Acceptance Of RPFS As Alternative Primary Endpoint Of The VISION Trial
7/31/2018 8:13:10 AM Endocyte Q2 Net Loss $11.6 Mln Or $0.17/Shr Vs Loss $11.7 Mln Or $0.28/Shr Last Year
7/9/2018 9:28:01 AM Endocyte, ITM Announce Long-Term Supply Agreement For No-Carrier-Added Lutetium-177
6/22/2018 8:03:31 AM Endocyte Says Multiple Presentations Related To Endocyte’s PSMA-617 Radioligand Therapy Will Be Presented At SNMMI
6/5/2018 8:05:35 AM Endocyte Announces Enrollment Of First Patient In Phase 3 VISION Trial Of 177Lu-PSMA-617 In Prostate Cancer
5/9/2018 2:28:03 PM Wedbush Is Increasing Endocyte, Inc. (ECYT) FY18 Estimate To -0.69 From -0.98
5/9/2018 2:27:45 PM Wedbush Is Increasing Endocyte, Inc. (ECYT) Q2 18 Estimate To -0.15 From -0.24
5/9/2018 8:10:19 AM Endocyte Announces The Lancet Oncology Publication Of Phase 2 Data From Prostate Cancer Trial Of (177)Lu-PSMA-617
5/9/2018 8:10:04 AM Endocyte Q1 Net Loss $8.6 Mln Or $0.16/Shr Vs Net Loss $11.5 Mln Or $0.27/Shr Last Year